Oshima Naohiro
Department of Pharmaceutical Sciences, International University of Health and Welfare.
Yakugaku Zasshi. 2017;137(2):173-177. doi: 10.1248/yakushi.16-00233-3.
Ephedra Herb is a crude drug for the treatment of headache, bronchial asthma, nasal inflammation, and the common cold. Although it has been considered that ephedrine alkaloids (EAs) are the principal active ingredients of Ephedra Herb, EAs are known to induce palpitations, hypertension, insomnia, and dysuria as major side effects. Therefore, the administration of EAs-containing drugs to patients with cardiovascular-related diseases is strongly contraindicated. Previously, we isolated herbacetin 7-O-neohesperidoside from Ephedra Herb. In addition, we found that herbacetin, a flavonoid aglycone in Ephedra Herb, had antiproliferative and analgesic effects. Therefore, the prospect of preparing safer natural medicines without the adverse effects associated with EAs was appealing. In this symposium review, to achieve the aim of producting a clinically useful Ephedra Herb extract with none of the adverse effects associated with EAs, I present an efficient preparation method of EAs-free Ephedra Herb extract, together with its chemical composition, antiproliferative effects, and a putative marker for quality control.
麻黄是一种用于治疗头痛、支气管哮喘、鼻炎症和普通感冒的天然药物。尽管一直认为麻黄生物碱(EAs)是麻黄的主要活性成分,但已知EAs会引发心悸、高血压、失眠和排尿困难等主要副作用。因此,强烈禁止向患有心血管相关疾病的患者施用含EAs的药物。此前,我们从麻黄中分离出了草棉黄素7-O-新橙皮糖苷。此外,我们发现麻黄中的黄酮苷元草棉黄素具有抗增殖和镇痛作用。因此,制备没有与EAs相关副作用的更安全天然药物的前景很有吸引力。在本次研讨会综述中,为了实现生产出无EAs相关副作用的临床可用麻黄提取物这一目标,我介绍了一种高效制备无EAs麻黄提取物的方法,以及其化学成分、抗增殖作用和一种质量控制的假定标志物。